Answers are grounded in this paper and cite their sources.
Among patients with progressive, refractory, or symptomatic desmoid tumors, sorafenib significantly prolonged progression-free survival and induced durable responses. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT02066181 .).
No takes yet. Share an insight, caveat, or question.
Gounder et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: